SC
TVTX icon

Steven Cohen’s Travere Therapeutics TVTX Stock Holding History

Steven Cohen’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,100
Closed -$462K – 4528
2025
Q4 		$462K Buy
+12,100
New +$393K ﹤0.01% 3274

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's TVTX Position: Q2 2026 in Review

Steven Cohen opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 478,860 shares worth $27.2M. The stake represents 0.03% of the portfolio and ranks #704 among its holdings. This is a return to the name: Steven Cohen previously reported a position in TVTX as recently as Q4 2025.

Steven Cohen first reported a position in TVTX in Q2 2015 and has held it in 29 quarters since. The position peaked at $40.2M in Q1 2021. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Steven Cohen held 478,860 shares of Travere Therapeutics worth $27.2M as of Q2 2026.
  • Travere Therapeutics was a new Steven Cohen position in Q2 2026.
  • Travere Therapeutics made up 0.03% of Steven Cohen's portfolio in Q2 2026, its #704 holding.
  • Steven Cohen first reported a position in Travere Therapeutics in Q2 2015 and has held it in 29 quarters since.
  • Steven Cohen's Travere Therapeutics position peaked at $40.2M in Q1 2021.
  • 317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.